LifespanningRx released the Peptide Explorer, a structured digital questionnaire that maps health goals across ten domains and flags potential peptide therapy candidates for clinician review. The tool screens responses against safety criteria before recommending further evaluation, positioning peptide therapy within a clinician-supervised framework rather than direct-to-consumer access.
Key Points
- Five-minute questionnaire maps ten health domains to 35 peptide therapy families
- Safety routing evaluates 122 criteria to restrict or prevent unsuitable candidates
- Clinician review required before prescription to licensed compounding pharmacy
Longevity Analysis
Peptide therapy increasingly appears in longevity medicine as a potential tool to address energy production, recovery capacity, hormonal signaling, and cognitive function—domains where individual variation is high and response prediction remains difficult. This tool represents a methodological shift toward structured intake and clinician-guided eligibility assessment, reducing speculative therapy selection while maintaining access for candidates who meet safety thresholds. The safety-first architecture acknowledges that peptide interventions carry contraindications and that proper sequencing matters; rushing into peptide use without understanding baseline function, medication interactions, and individual tolerance can undermine rather than support sustained health gains.
Original published by LT Wire.